• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Viruses . Comparative Analyses of the Antiviral Activities of IgG and IgA Antibodies to Influenza A Virus M2 Protein

tetano

Editor, Senior Moderator
Viruses


. 2020 Jul 20;12(7):E780.
doi: 10.3390/v12070780.
Comparative Analyses of the Antiviral Activities of IgG and IgA Antibodies to Influenza A Virus M2 Protein


Kosuke Okuya[SUP] 1 [/SUP], Nao Eguchi[SUP] 1 [/SUP], Rashid Manzoor[SUP] 1 [/SUP], Reiko Yoshida[SUP] 1 [/SUP], Shinji Saito[SUP] 2 [/SUP], Tadaki Suzuki[SUP] 3 [/SUP], Michihito Sasaki[SUP] 4 [/SUP], Takeshi Saito[SUP] 1 [/SUP], Yurie Kida[SUP] 1 [/SUP], Akina Mori-Kajihara[SUP] 1 [/SUP], Hiroko Miyamoto[SUP] 1 [/SUP], Osamu Ichii[SUP] 5 [/SUP], Masahiro Kajihara[SUP] 1 [/SUP], Hideaki Higashi[SUP] 6 7 [/SUP], Ayato Takada[SUP] 1 7 [/SUP]



Affiliations
Free article

Abstract

The influenza A virus (IAV) matrix-2 (M2) protein is an antigenically conserved viral envelope protein that plays an important role in virus budding together with another envelope protein, hemagglutinin (HA). An M2-specific mouse monoclonal IgG antibody, rM2ss23, which binds to the ectodomain of the M2 protein, has been shown to be a non-neutralizing antibody, but inhibits plaque formation of IAV strains. In this study, we generated chimeric rM2ss23 (ch-rM2ss23) IgG and IgA antibodies with the same variable region and compared their antiviral activities. Using gel chromatography, ch-rM2ss23 IgA were divided into three antibody subsets: monomeric IgA (m-IgA), dimeric IgA (d-IgA), and trimeric and tetrameric IgA (t/q-IgA). We found that t/q-IgA had a significantly higher capacity to reduce the plaque size of IAVs than IgG and m-IgA, most likely due to the decreased number of progeny virus particles produced from infected cells. Interestingly, HA-M2 colocalization was remarkably reduced on the infected cell surface in the presence of ch-rM2ss23 antibodies. These results indicate that anti-M2 polymeric IgA restricts IAV budding more efficiently than IgG and suggest a role of anti-M2 IgA in cross-protective immunity to IAVs.

Keywords: IgA; antibody; budding inhibition; cross-protective immunity; influenza A virus; matrix 2 protein.
 
Back
Top Bottom